Stockreport

Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval [Yahoo! Finance]

Disc Medicine, Inc.  (IRON) 
PDF Agreement on proposed primary endpoint of average monthly time in sunlight during the last month following a 6-month treatment period Potential for accelerated approv [Read more]